Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Ipsen gets rights to Santhera's fipamezole; terminated

Executive Summary

Ipsen has received global development and marketing rights to Santhera Pharmaceuticals AG's (therapies for neuromuscular diseases) fipamezole for levodopa-induced dyskinesia in Parkinson's disease patients. The license excludes North America (where Biovail Corp. is the licensee) and Japan (where Santhera retains rights).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register